PathMaker Neurosystems Inc. announces selection as a Semi-Finalist for the 2015 BioVision Investor Conference
Boston, MA (April 1, 2015) – PathMaker Neurosystems Inc. (“PathMaker”) today announced that it was selected as an invited Semi-Finalist for the BioVision Investor Conference, to be held on April 14-16 in Lyon, France. BioVision is a leading annual forum on life sciences, co-organized jointly with France Biotech and Lyonbiopole. This year, 25 innovative life science companies were selected to present to an audience of leading venture capitalists and corporate investors. These 25 companies included 15 Biotech companies and 10 Medtech companies, and PathMaker Neurosystems was selected as 1 of the 10 Medtech companies invited to present as a Semi-Finalist. “PathMaker Neurosystems is honored and excited to have been selected as one of the companies presenting at this year’s BioVision conference,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “We are developing non-invasive neuromodulation technologies that promise to enable the treatment of numerous groups of patients who currently have inadequate treatment options.”
About PathMaker Neurosystems Inc.
PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. tsDCS is a novel modality for non-invasive neuromodulation that has only emerged within the last five years, being driven by fundamentally new understandings of spinal circuit biology made by our company’s scientific advisors and their clinical work in treating patients with paralysis, muscle weakness and muscle tone disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology we are developing promises to open up entirely new methods of treating these patients.
Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, email@example.com